• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CLRB

    Cellectar Biosciences Inc.

    Subscribe to $CLRB
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

    IPO Year:

    Exchange: NASDAQ

    Website: cellectar.com

    Peers

    $SELB
    $XBIO
    $ATNM

    Recent Analyst Ratings for Cellectar Biosciences Inc.

    DatePrice TargetRatingAnalyst
    12/5/2024$13.00Buy
    Ladenburg Thalmann
    See more ratings

    Cellectar Biosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

      FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, May 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:53983Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

      5/7/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Announces Plan to Explore Strategic Alternatives

      FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company's board of directors has approved the engagement of Op

      4/30/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

      Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced fin

      3/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Present at the 37th Annual Roth Conference

      FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows: Date: Monday, March 17Time: 8:30 AM Eastern TimeWebcast: Click HERE A replay of the corporate presentation will be available on the Events section of the company's Investor Relations website. About Cellectar Biosciences, Inc.Cellectar Biosciences is a late-stage clinical biopharmaceutical

      3/11/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

      FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, March 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:           25759Click HERE A replay of the call will be available on the Events section of the company's Investor Relations website.

      3/5/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

      FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows: Date: Wednesday, February 12, 2025Time: 12:00 PM Eastern TimeWebcast: Click HERE A replay of the corporate presentation will be available on the Events section of the company's investor relations website. About Cellectar Biosciences

      2/5/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

      Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom's Macroglobulinemia Plans to Advance Iopofosine I 131 Internally, Through Strategic Partnerships and Other Approaches; Finalizing Confirmatory Study and Pathway for US FDA Accelerated Approval and EMA Prime Marketing Authorization Advancing Radiotherapeutic Assets including Alpha- and Auger-emitting Radioconjugates into Phase 1/2a Solid Tumor Studies FLORHAM PARK, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical c

      1/12/25 6:00:00 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

      Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeut

      12/10/24 5:00:00 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

      NorthStar to provide non-carrier added actinium-225 (n.c.a Ac-225) to Cellectar for use in its expanded portfolio of clinical programs This includes CLR 121225 an actinium-labeled phospholipid ether (PLE), expected to enter a Phase 1 study in pancreatic cancer in 2025 NorthStar Medical Radioisotopes, LLC today announced the signing of a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ:CLRB) under which Cellectar will acquire and integrate NorthStar's n.c.a. Ac-225 into Cellectar's proprietary Phospholipid Ethers (PLE) delivery platform to expand the platform's capability to produce a diverse range of radiotherapeutic molecules. NorthStar is a global innova

      11/21/24 8:00:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

      Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise up to an additional $73.3 million Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2024, and provided a corporate update. "We achieved important clinical, operational

      11/18/24 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. Financials

    Live finance-specific insights

    See more
    • Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

      FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, May 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:53983Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

      5/7/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

      Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced fin

      3/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

      FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, March 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:           25759Click HERE A replay of the call will be available on the Events section of the company's Investor Relations website.

      3/5/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

      Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise up to an additional $73.3 million Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2024, and provided a corporate update. "We achieved important clinical, operational

      11/18/24 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

      FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Monday, November 18, 2024Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:80659Webcast:Click HERE   A replay of the call will be available on the Events section of the company's investor relations website. About

      11/11/24 4:05:00 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

      FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update. "With our recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom's macroglobulinemia, we remain focused on filing our WM NDA in the fourth quarter of this year," said James Caruso, president and CEO of Cellectar. "We anticipate an accelerated six-month NDA review period and continue to prepar

      8/13/24 6:40:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

      FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: Conference Call & Webcast Details:Date:                Tuesday, August 13, 2024Time:                8:30 am Eastern TimeToll Free:         

      8/8/24 5:15:14 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

      FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: Conference Call & Webcast Details:Date:Tuesday, August 13, 2024Time:8:30 am Eastern TimeToll Free:1-800-717-1738Webcast:Click HERE   A replay of

      8/8/24 4:05:00 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

      56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab) FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131, a potential first-in-class, targeted radi

      7/23/24 6:40:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

      FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 2024, at 8:00 a.m., EDT, to provide a comprehensive overview of recent data from its pivotal trial of iopofosine I 131 in Waldenstrom's macroglobulinemia, the current treatment landscape, unmet needs for patients with this disease, and opportunities to improve patient outcomes. The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and

      6/27/24 6:40:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target

      Ladenburg Thalmann resumed coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $13.00

      12/5/24 8:32:15 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 4:47:59 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 1:26:20 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      8/14/24 7:15:55 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      7/11/24 5:37:40 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectar Biosciences Inc. (Amendment)

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      4/25/24 8:01:31 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectar Biosciences Inc. (Amendment)

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      2/14/24 8:31:57 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cellectar Biosciences Inc.

      SC 13G - Cellectar Biosciences, Inc. (0001279704) (Subject)

      2/14/24 4:51:40 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectar Biosciences Inc. (Amendment)

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      2/14/24 4:29:43 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectar Biosciences Inc. (Amendment)

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      2/14/24 3:23:01 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectar Biosciences Inc. (Amendment)

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      2/7/24 6:58:32 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Longcor Jarrod bought $8,400 worth of shares (30,000 units at $0.28), increasing direct ownership by 56% to 83,141 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      3/12/25 9:44:18 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Swirsky Douglas J

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:07:24 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Neis John

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:06:31 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Loren Stefan

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:05:52 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Longcor Jarrod

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:05:07 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Kolean Chad J

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:04:18 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Driscoll Frederick W

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:03:34 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chanan-Khan Asher

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:02:37 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Caruso James V

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:01:16 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Longcor Jarrod

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      6/18/24 5:04:49 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. SEC Filings

    See more
    • Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

      5/1/25 6:04:27 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cellectar Biosciences Inc.

      DEFA14A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      4/28/25 4:36:07 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Cellectar Biosciences Inc.

      DEF 14A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      4/28/25 4:31:16 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Cellectar Biosciences Inc.

      PRE 14A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      4/18/25 4:32:52 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

      3/17/25 4:30:21 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

      3/13/25 7:15:31 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Cellectar Biosciences Inc.

      10-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

      3/13/25 6:50:22 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cellectar Biosciences Inc.

      SCHEDULE 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      2/13/25 3:49:47 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Cellectar Biosciences Inc.

      424B3 - Cellectar Biosciences, Inc. (0001279704) (Filer)

      2/7/25 4:14:52 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Cellectar Biosciences Inc.

      EFFECT - Cellectar Biosciences, Inc. (0001279704) (Filer)

      2/7/25 12:15:16 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

      William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "

      10/17/23 8:00:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

      ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

      3/27/23 4:05:00 PM ET
      $CLRB
      $MXCT
      $REXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Major Pharmaceuticals
    • Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

      FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior vice president hematology at TG Therapeutics, he oversaw the sales, marketing and analytics teams for the hematology franchise. Prior to TG Therapeutics, Mr. Lea served as vice president, hematology

      11/30/22 8:30:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Announces Key Commercial Team Appointments

      Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances David Lasecki Appointed Executive Director, Strategic Alliances FLORHAM PARK, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced the appointment of Matthew Hagan as vice president, marketing and strategic alliances and David Lasecki as executive director, strategic alliances. "Matt and David each bring a wealth of experience and strong track records of success in the launching and marketing of oncology therapeutic

      4/12/22 8:30:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

      SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin

      11/15/21 11:00:00 AM ET
      $CLRB
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

      FLORHAM PARK, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced Laurence Reilly, M.D., LL.M as its interim chief medical officer. Dr. Reilly will oversee the company's clinical development programs and report to Chief Executive Officer James Caruso. He succeeds John Friend, MD, who is stepping down for personal reasons but will stay on through mid-November to finalize the ongoing transition. "We are delighted to welcome Laurence to our executive team and look forward to his leadership of our clinical develo

      11/2/21 8:30:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

      BOSTON--(BUSINESS WIRE)--AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer effective February 1, 2021. A seasoned financial and operational life sciences executive, Mr. Swirsky will be responsible for building out the Company’s financial, accounting, and facility functions to support AavantiBio’s growth and clinical development of its diversified pipeline of gene therapies. Mr. Swirsky, brings to AavantiBio more than 25 years of strategic, financial, and operational experience in the biopharmaceutical and healthcare sectors, inclu

      3/3/21 7:00:00 AM ET
      $OCUP
      $CLRB
      $PGEN
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cellectar Biosciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Longcor Jarrod bought $8,400 worth of shares (30,000 units at $0.28), increasing direct ownership by 56% to 83,141 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      3/12/25 9:44:18 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care